Neuromodulators, dermal fillers, biostimulators, and the longevity question. Label-first, comparison-shaped.
FDA warnings on needle-free dermal filler devices (Hyaluron Pens). High-pressure jet injection carries severe risks of skin necrosis, permanent blindness, and clinical…
An analysis of 10 FDA injectable labels: every botulinum toxin carries the same boxed warning, while Kybella does not. A plain map of what the prescribing information…
Bellafill is the only FDA-approved permanent dermal filler in the US — PMMA microspheres that stay for years. What it is approved for, who is not a candidate, and why it…
Full FAERS analysis of 1,968 deoxycholic-acid (Kybella) reports: nerve-injury terms lead, off-label and 'drug ineffective' rank high, and a paradoxical fat-growth signal…
Regenerative aesthetics mapped from 77 trials and the FDA record: PRP leads the research, exosomes and polynucleotides have no U.S. approval, and unapproved stem-cell…
22,242 FDA MAUDE reports for dermal fillers (product code LMH): the Juvéderm family leads at 55%, HA fillers drive 72% of all reports, and a 2025 surge pushed annual…
Kybella causes expected swelling and numbness, but two side effects are FDA-flagged: temporary jaw-nerve injury and trouble swallowing. What the label, trials, and…
Sculptra (PLLA) can cause firm nodules months after injection that cannot be dissolved like HA filler. What the FDA trial and clinical literature say about incidence,…
Relfydess is the first ready-to-use liquid neuromodulator. FDA accepted the BLA resubmission in Feb 2026. Phase 3 data show day-1 onset and up to 6-month duration for…
TrenibotE is the first serotype E neurotoxin submitted for FDA approval. Onset in 8 hours, duration of 2–3 weeks, over 2,100 patients studied. April 2026 CRL addresses…